Live Free or Die Legal
This website is not an official source of law. This website does not provide legal advice. For official legal materials, verify against the relevant court, legislature, agency, or other official source. Legal information may be incomplete, outdated, or incorrectly processed. Consult a qualified attorney for advice about a specific legal matter.

This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 318-B:49 · Electronic Registry System

Title
XXX: OCCUPATIONS AND PROFESSIONS
Chapter
318-B · CONTROLLED DRUG ACT
Status
current
Official source linked
Yes
Official source Copy section link

318-B:49 Electronic Registry System. –

Copy link
I.

(a) Retail establishments shall use an electronic registry system to record the sale of products made pursuant to RSA 318-B:48. The electronic registry system shall have the capacity to block a sale of nonprescription drug products containing ephedrine, pseudoephedrine, or phenylpropanolamine that would result in a purchaser exceeding the lawful daily or monthly amount. The system shall contain an override function that may be used by an agent of a retail establishment who is dispensing the drug product and who has a reasonable fear of imminent bodily harm to his or her person or to another person if the transaction is not completed. The system shall create a record of each use of the override mechanism.

Copy link
(b)

The electronic registry system shall be available free of charge to the state of New Hampshire, retail establishments, and local law enforcement agencies.

Copy link
(c)

The electronic registry system shall operate in real time to enable communication among in-state users and users of similar systems in neighboring states.

Copy link
(d)

The state shall use the National Precursor Log Exchange (NPLEx) online portal or its equivalent to host New Hampshire's electronic registry system.

Copy link
II.

(a) Prior to completing a sale under RSA 318-B:48, a retail establishment shall require the person purchasing the drug product to present a current, valid government-issued identification document. The retail establishment shall record in the electronic registry system:

Copy link
(1)

The name and address of the purchaser;

Copy link
(2)

The name of the drug product and quantity of ephedrine, pseudoephedrine, and phenylpropanolamine sold in grams;

Copy link
(3)

The date and time of purchase;

Copy link
(4)

The form of identification presented, the issuing government entity, and the corresponding identification number; and

Copy link
(5)

The name of the person selling or furnishing the drug product. (b)(1) If the retail establishment experiences an electronic or mechanical failure of the electronic registry system and is unable to comply with the electronic recording requirement, the retail establishment shall maintain a written log or an alternative electronic recordkeeping mechanism until the retail establishment is able to comply fully with this subdivision.

Copy link
(2)

If the region of the state where the retail establishment is located does not have broadband Internet access, the retail establishment shall maintain a written log or an alternative electronic recordkeeping mechanism until broadband Internet access becomes accessible in that region. At that time, the retail establishment shall come into compliance with this subdivision.

Copy link
(c)

A retail establishment shall maintain all records of drug product purchases made pursuant to this subdivision for a minimum of 2 years.

Copy link
III.

A retail establishment shall display a sign at the register provided by NPLEx or its equivalent to notify purchasers of drug products containing ephedrine, pseudoephedrine, or phenylpropanolamine that:

Copy link
(a)

The purchase of the drug product or products shall result in the purchaser's identity being listed on a national database; and

Copy link
(b)

The purchaser has the right to request the transaction number for any purchase that was denied pursuant to this subdivision. Source. 2018, 124:1, eff. Jan. 1, 2019.

Copy link

Source note

Source. 2018, 124:1, eff. Jan. 1, 2019.

Source history

  • 2018, 124:1, eff. Jan. 1, 2019

Related materials

Bill relationships

  • 2026 HB1235 reference

    es on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This section s

  • 2026 HB1235-FN reference

    es on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This section s

  • 2026 HB1237 reference

    owledging the receipt and understanding of the policy. XXII. Excluding the drugs described in 49 C.F.R. section 392.4 of the federal Motor Carrier regulations and outlined under RSA 318-B, the only drugs that may be transported are those legally prescribed by a licensed physician, in their original container, and in the possession of the person who is prescribed them. XXIII. A tow business whose driver

  • 2026 HB1423 amend · effective 2027-01-01

    ffect without the invalid provision or application, and to this end the provisions of this act are declared to be severable. 3 New Subdivision; Synthetic Kratom Policy. Amend RSA 318-B by inserting after section 50 the following new subdivision: Synthetic Kratom Policy 318-B:51 Definitions. In this subdivision, "synthetic kratom" or "semisynthetic kratom" means: I. An alkaloid or alkaloid de

  • 2026 HB1423-FN amend · effective 2027-01-01

    ffect without the invalid provision or application, and to this end the provisions of this act are declared to be severable. 3 New Subdivision; Synthetic Kratom Policy. Amend RSA 318-B by inserting after section 50 the following new subdivision: Synthetic Kratom Policy 318-B:51 Definitions. In this subdivision, "synthetic kratom" or "semisynthetic kratom" means: I. An alkaloid or alkaloid de

  • 2026 HB1796 reference · effective 2027-01-01

    arch, or arrest of a person or for a violation of probation or parole, and psilocybin that relates to the conduct is not contraband or subject to seizure or forfeiture pursuant to RSA 318-B: (a) A cultivator or provider possessing or transporting not more than an adequate supply of psilocybin for medical purposes as defined by department rule; and (b) A provider administering or a qualified patient t

  • 2026 HB1796-FN reference · effective 2027-01-01

    arch, or arrest of a person or for a violation of probation or parole, and psilocybin that relates to the conduct is not contraband or subject to seizure or forfeiture pursuant to RSA 318-B: (a) A cultivator or provider possessing or transporting not more than an adequate supply of psilocybin for medical purposes as defined by department rule; and (b) A provider administering or a qualified patient t

  • 2026 HB186 reference

    of Drugs. Any person who drives on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This

  • 2026 HB186-FN-A amend

    . 5 Model Drug Dealer Liability Act; Definition of Illegal Drug. Amend RSA 318-C:4, I to read as follows: I. "Illegal drug" means any drug which is a schedule I-IV drug under RSA 318-B, the possession, use, manufacture, sale, or transportation of which is not otherwise authorized by law. 6 New Chapter; Regulation of Cannabis. Amend RSA by inserting after chapter 318-E the following new chapter: CH

  • 2026 HB194 reference · effective 2027-01-01

    als under pharmacist supervision. A licensee or registrant of the board of pharmacy shall independently determine whether: (a) The act is expressly prohibited by: (1) This chapter; (2) The controlled drug act, RSA 318-B; (3) The rules of the board of pharmacy; or (4) Any other applicable state or federal laws or regulations; (b) The act is consistent with the individual's education, training, and experience; and (c) Performan

  • 2026 HB194-FN reference · effective 2027-01-01

    licensee or registrant of the board of pharmacy shall independently determine whether: (a) The act is expressly prohibited by: (1) This chapter; (2) The controlled drug act, RSA 318-B; (3) The rules of the board of pharmacy; or (4) Any other applicable state or federal laws or regulations; (b) The act is consistent with the individual's education, training, and experience; and (c) Performance

  • 2026 SB465 amend · effective 2027-01-01

    s a schedule III controlled drug. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Controlled Drug Act; Xylazine. Amend RSA 318-B by inserting after section 1-c the following new section: 318-B:1-d Xylazine. I. Notwithstanding the provisions of RSA 318-B:1-a, relative to scheduling by rulemaking of the commissioner of the department of healt